Table 2. Targeted Resequencing Identifies Clinically Actionable Mutations.

Clinical characteristics of 14 patients with advanced melanoma whose tumors underwent NGS. Mutation calls and mutational profiles, with potentially actionable mutations are highlighted in red. Somatic mutations validated by CLIA-certified testing and reported to physicians are underlined.

Pt No	Age	Race	Sex	Non Synonymous Single Nucleotide and Indel Variations	Survival (Months)
1	87	W	M		0.8
2	38	W	M		11+
3	69	W	M		71
4	57	W	M		37
5	28	W	M		12
6	31	W	M		17
7	70	W	M		74
8	41	W	M		9
9	70	Afr	F		17
10	37	As	F	KDM6AT726K PTCH1A741V TP53V31I	21
11	73	W	F		16
12	24	W	F		204
13	38	W	M		31
14	72	W	F		4
M1	-	-	-	EPHB6P165PS TSC2FS	N/A
M2	-	-	-		N/A
M3	-	-	-		N/A
M4	-	-	-		N/A